A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Dexamethasone
Related studies linked through entity extraction aliases.
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Analgesic Effect of IV Acetaminophen in Tonsillectomies
- Status
- COMPLETED
- Phase
- PHASE2
Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%
- Status
- COMPLETED
- Phase
- NA
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
- Status
- COMPLETED
- Phase
- PHASE1
Dexamethasone Dyspnea Study
- Status
- COMPLETED
- Phase
- PHASE2
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Status
- TERMINATED
- Phase
- PHASE3
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
- Status
- WITHDRAWN
- Phase
- PHASE2